Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2(+) γδ T cell cytotoxicity in a perforin-dependent manner. by Fowler, DW et al.
1 3
Cancer Immunol Immunother (2017) 66:1205–1215
DOI 10.1007/s00262-017-2011-1
ORIGINAL ARTICLE
Zoledronic acid renders human M1 and M2 macrophages 
susceptible to Vδ2+ γδ T cell cytotoxicity in a perforin‑dependent 
manner
Daniel W. Fowler1  · John Copier1 · Angus G. Dalgleish1 · Mark D. Bodman‑Smith1 
Received: 16 January 2017 / Accepted: 2 May 2017 / Published online: 13 May 2017 
© The Author(s) 2017. This article is an open access publication
the perforin inhibitor concanamycin A. These findings sug-
gest that ZA can render M1 and M2 Mφs susceptible to 
Vδ2+ T cell cytotoxicity in a perforin-dependent manner, 
which has important implications regarding the use of ZA 
in cancer immunotherapy.
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Abbreviations
CCL  Chemokine (C–C motif) ligand
CFSE  Carboxyfluorescein succinimidyl ester
CMA  Concanamycin A
FSC  Forward scatter
G  Gate
IPP  Isopentenyl pyrophosphate
LSD  Least significant difference
Mφ  Macrophage
MFI  Mean (arithmetic) fluorescence intensity
NBP  Nitrogen-containing bisphosphonate
SD  Standard deviation
SSC  Side scatter
TAM  Tumour-associated macrophage
ZA  Zoledronic acid
Introduction
Human peripheral blood contains a subpopulation of γδ T 
cells that express TCRs composed of Vγ9 and Vδ2 subu-
nits. These cells—referred to here as Vδ2+ T cells—typi-
cally represent 0.5–5% of peripheral blood T cells and 
exert potent cytotoxicity against their target cells.
Vδ2+ T cells detect intermediates of isoprenoid bio-
synthesis, namely isopentenyl pyrophosphate (IPP) and 
Abstract Vδ2+ T cells are a subpopulation of γδ T cells 
in humans that are cytotoxic towards cells which accumu-
late isopentenyl pyrophosphate. The nitrogen-containing 
bisphosphonate, zoledronic acid (ZA), can induce tumour 
cell lines to accumulate isopentenyl pyrophosphate, thus 
rendering them more susceptible to Vδ2+ T cell cyto-
toxicity. However, little is known about whether ZA ren-
ders other, non-malignant cell types susceptible. In this 
study we focussed on macrophages (Mφs), as these cells 
have been shown to take up ZA. We differentiated periph-
eral blood monocytes from healthy donors into Mφs and 
then treated them with IFN-γ or IL-4 to generate M1 and 
M2 Mφs, respectively. We characterised these Mφs based 
on their phenotype and cytokine production and then tested 
whether ZA rendered them susceptible to Vδ2+ T cell cyto-
toxicity. Consistent with the literature, IFN-γ-treated Mφs 
expressed higher levels of the M1 markers CD64 and IL-
12p70, whereas IL-4-treated Mφs expressed higher levels 
of the M2 markers CD206 and chemokine (C–C motif) 
ligand 18. When treated with ZA, both M1 and M2 Mφs 
became susceptible to Vδ2+ T cell cytotoxicity. Vδ2+ 
T cells expressed perforin and degranulated in response 
to ZA-treated Mφs as shown by mobilisation of CD107a 
and CD107b to the cell surface. Furthermore, cytotoxicity 
towards ZA-treated Mφs was sensitive—at least in part—to 
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(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate. IPP is 
generated by the endogenous mevalonate pathway as well 
as the exogenous 1-deoxy-d-xylulose-5-phosphate path-
way, whereas (E)-4-hydroxy-3-methyl-but-2-enyl pyroph-
osphate is generated by the 1-deoxy-d-xylulose-5-phos-
phate pathway only [1]. The mevalonate pathway is often 
dysregulated in malignant and infected cells, resulting in 
accumulation of IPP and increased susceptibility to Vδ2+ 
T cell cytotoxicity [2, 3]. Moreover, certain cells accumu-
late IPP when exposed to the nitrogen-containing bisphos-
phonate (NBP), zoledronic acid (ZA) [4], a synthetic drug 
that inhibits an enzyme of the mevalonate pathway called 
farnesyl pyrophosphate synthase [5]. Although the precise 
mechanism of IPP and (E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate recognition by Vδ2+ T cells has yet to be 
determined, evidence suggests that it is TCR dependent and 
involves butyrophilin 3A1 [6].
Zoledronic acid is typically used to treat complications 
associated with excessive bone resorption in diseases such 
as osteoporosis, Paget’s disease and metastatic bone dis-
ease [7]. In terms of its mode of action, ZA binds to bone 
and disrupts the activity of bone remodelling cells called 
osteoclasts [8]. ZA also has potential as an immunotherapy 
for cancer, the proof of concept for which has already been 
demonstrated in clinical trials [9–11]. Although in can-
cer its mode of action is poorly understood, experiments 
in vitro have shown that tumour cell lines from a broad 
range of haematological and solid malignancies become 
more susceptible to Vδ2+ T cell cytotoxicity when exposed 
to ZA, suggesting a role for Vδ2+ T cells [12–14]. How-
ever, the capacity for ZA to induce susceptibility in other, 
non-malignant cell types is poorly characterised and could 
provide insight that helps to better understand the effects of 
this drug and improve its clinical application. In this study 
we have focussed on macrophages (denoted here as Mφs) 
because these cells have been shown recently to take up 
NBPs in vivo [15] and are implicated in the progression of 
cancer [16].
Mφs are tissue-resident phagocytic cells that play a criti-
cal role in tissue repair as well as immunity against patho-
genic infection and malignant transformation [17]. Mφs 
display functional plasticity that is intricately linked to their 
surrounding microenvironment [18]. Researchers have cat-
egorised the different functional states of Mφs according to 
their capacity to either promote inflammation or suppress 
it. At one end of the spectrum are pro-inflammatory Mφs, 
also referred to as M1 or classically activated Mφs, and at 
the other end are anti-inflammatory Mφs, also known as 
M2 or alternatively activated Mφs [19]. IFN-γ and IL-4 
have been identified as key drivers of these opposing M1 
and M2 phenotypes, respectively [19].
As part of our ongoing studies into how ZA stimulates 
anti-tumour responses in Vδ2+ T cells, we identified a 
previously unexplored effect involving Vδ2+ T cell target-
ing of myeloid cells. Recently, we showed that ZA can ren-
der peripheral blood monocytes susceptible to Vδ2+ T cell 
cytotoxicity in vitro [20]. In a subsequent study by Junan-
kar et al., tumour-associated Mφs (TAMs) in breast cancer 
were identified as important targets for NBPs in vivo [15]. 
Therefore, we further explored the concept of Vδ2+ T cell 
targeting of myeloid cells, and found that ZA can render 
M1 and M2 Mφs susceptible to Vδ2+ T cell cytotoxic-
ity. Furthermore, we found that Vδ2+ T cell cytotoxicity 
towards ZA-treated Mφs was dependent—at least in part—
on perforin. This novel insight into the interplay between 
Vδ2+ T cells and Mφs has important implications regard-
ing the use of ZA in cancer immunotherapy.
Materials and methods
PBMC isolation
Anonymised leukocyte cones from healthy donors were 
obtained from the National Health Service blood transfu-
sion unit at St. George’s Hospital, London. PBMCs were 
isolated by density-adjusted centrifugation using His-
topaque-1077 (Sigma-Aldrich). RBCs were lysed with 
ammonium chloride solution and platelets removed by 
slow-speed centrifugation. PBMCs were resuspended at 
2 × 107 cells/ml of freezing medium (45% RPMI-1640, 
45% FBS and 10% DMSO; all from Sigma-Aldrich) and 
frozen at −80 °C in Mr Frosty freezing containers (Thermo 
Scientific) prior to transferring them to liquid nitrogen.
Cell culture
All cell culture was carried out in a humidified incubator 
at 37 °C with 5%  CO2. To generate Mφs, monocytes were 
isolated from PBMCs using CD14 microbeads according to 
the manufacturer’s instructions (Miltenyi Biotec). Mono-
cytes were resuspended in serum-free medium (RPMI-
1640 containing 2 mM l-glutamine, 100 units/ml penicillin 
and 100 μg/ml streptomycin; all from Sigma-Aldrich) at a 
density of 3.8 × 105 cells/ml, and 200 μl, 2 or 5 ml of cell 
suspension added per well of 96-well, 12-well or 6-well tis-
sue culture plates, respectively (Thermo Scientific). Mono-
cytes were cultured for 2 h, after which time the majority 
of cells were adherent to the tissue culture plate. This pro-
cess is known to activate monocytes and initiate the mac-
rophage colony-stimulating factor production required for 
Mφ differentiation [21]. The adherent monocytes were then 
cultured for 10 days in complete medium (RPMI-1640 
containing 10% FBS, 2 mM l-glutamine, 100 units/ml 
penicillin and 100 μg/ml streptomycin), after which time 
the monocytes had differentiated into Mφs, as indicated by 
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the morphological changes and plastic adherence observed 
using light microscopy. M1 and M2 Mφs were generated 
by adding 25 ng/ml of recombinant human IFN-γ or IL-4 
(R and D Systems), respectively, on day 7. Mφs that had 
not been treated with IFN-γ or IL-4 (designated M0s) were 
used as controls throughout. 10 μM ZA (Sigma-Aldrich) 
was added to the Mφs on day 9. To generate pure popula-
tions of Vδ2+ T cells, PBMCs were resuspended at 2 × 106 
cells/ml of complete medium containing 1 μM ZA and 
5 ng/ml recombinant human IL-2 (R and D Systems), 
and 250 μls of cell suspension added per well of 96-well 
round-bottomed tissue culture plates (Thermo Scientific). 
The cells were cultured for 9 days and fed every 2–3 days 
with fresh medium containing 5 ng/ml IL-2. Dead cells and 
non-γδ T cells were depleted sequentially using dead cell 
removal kits and TCRγδ negative isolation kits according 
to the manufacturer’s instructions (Miltenyi Biotec). The 
purity of Vδ2+CD3+ cells was assessed by flow cytometry 
using PE-conjugated mouse anti-human Vδ2 (clone 123R3; 
Miltenyi Biotec) and PerCP-conjugated mouse anti-human 
CD3 (clone SK7; Biolegend) or FITC-conjugated mouse 
anti-human CD3 (clone HIT3a; Becton–Dickinson). For 
one donor, a high percentage of Vδ1+CD3+ cells was 
detected post-isolation, and so Vδ1+ cells were depleted 
using allophycocyanin-conjugated recombinant human 
anti-Vδ1 (clone REA173; Miltenyi Biotec) and anti-allo-
phycocyanin microbeads according to the manufacturer’s 
instructions (Miltenyi Biotec; supplementary Fig. 1). We 
speculate that this donor’s PBMCs had a particularly high 
percentage of Vδ1+ T cells prior to ZA and IL-2 stimula-
tion and/or their Vδ1+ T cells underwent bystander expan-
sion in response to ZA and IL-2.
Flow cytometry
Day 10 Mφs in six-well tissue culture plates were washed 
twice in PBS (Sigma-Aldrich) and cultured for 15 min in 
PBS containing 0.25% trypsin (Life Technologies) and 
2 mM EDTA (Sigma-Aldrich). Cells were detached by 
repeated pipetting and then washed in complete medium 
to deactivate the trypsin. Mφs were resuspended in flow 
cytometry buffer (PBS with 1% BSA and 0.09% sodium 
azide; all from Sigma-Aldrich) containing either FITC-
conjugated mouse anti-human CD64 (clone 10.1; Becton–
Dickinson) or PE-conjugated mouse anti-human CD206 
(clone 19.2; Becton–Dickinson). Matched isotype con-
trols were used to determine the amount of background 
expression. After 10 min at room temperature, cells were 
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Fig. 1  Characterisation of M1 and M2 Mφs treated with or with-
out ZA. a, b Flow cytometry was used to measure the expression of 
CD64 and CD206 on M0, M1 and M2 Mφs treated with (orange) or 
without (blue) ZA for the last 18 h of culture. a Representative flow 
cytometry plots from one of six donors (−ZA). Dead cells and debris 
were excluded based on forward scatter (FSC) and side scatter (SSC) 
using gate (G) 1. Unfilled overlays = test, filled overlays = isotype. 
Numbers on the plots are percentage of cells within the marker. b 
Individual data points and means for six donors. Test MFIs for the 
total G1 population were divided by isotype controls to obtain rela-
tive MFIs. c M0, M1 and M2 Mφs treated with (orange) or without 
(blue) ZA for the last 18 h of culture were cultured overnight in fresh 
medium with or without 100 ng/ml LPS. The concentration of IL-
12p70 and CCL18 in culture supernatants was measured using ELI-
SAs. Data for IL-12p70 is in the presence of LPS, whereas data for 
CCL18 is in the absence of LPS. Individual data points and means 
for six donors are shown. For b and c, data were analysed by repeated 
measures two-way ANOVA and comparisons between means carried 
out using Tukey’s multiple comparison tests. *** and **** indicate p 
values of <0.001 and <0.0001, respectively. Statistical differences for 
comparisons within the +ZA (orange) data sets are not shown
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washed in flow cytometry buffer and fixed in CellFIX (Bec-
ton–Dickinson). Perforin expression in Vδ2+ T cells was 
assessed in PBMCs cultured with ZA and IL-2 for 0, 1 
and 9 days as described in "Cell culture". Cells were resus-
pended in flow cytometry buffer containing PE-conjugated 
mouse anti-human Vδ2 (clone 123R3; Miltenyi Biotec) and 
PerCP-conjugated mouse anti-human CD3 (clone SK7; 
Biolegend). After 10 min at room temperature, cells were 
washed in flow cytometry buffer and simultaneously fixed 
and permeabilised using Cytofix/Cytoperm (Becton–Dick-
inson) according to the manufacturer’s instructions. Cells 
were washed and resuspended in Perm/Wash buffer (Bec-
ton–Dickinson) and then labelled with FITC-conjugated 
mouse anti-human perforin (clone δG9; Becton–Dickinson) 
or matched isotype controls. After 10 min at room tempera-
ture, cells were washed in Perm/Wash buffer and resus-
pended in flow cytometry buffer. Samples were acquired 
on an LSR II flow cytometer (Becton–Dickinson) and ana-
lysed using FlowJo software. All comparatively analysed 
samples were acquired on the same day except for the time 
course of perforin expression where day 0, 1 and 9 samples 
were acquired on different days. The mean fluorescence 
intensity (MFI) values stated throughout are arithmetic 
means.
ELISAs
Day 10 Mφs in 12-well tissue culture plates were washed 
twice in PBS and cultured overnight in complete medium 
(1 ml/well) with or without 100 ng/ml LPS (E.coli 
0127:B8; Sigma-Aldrich). The concentration of IL-12p70 
and chemokine (C–C motif) ligand (CCL) 18 within cell-
free culture supernatants was determined using DuoSet 
ELISA kits according to the manufacturer’s instructions (R 
and D Systems). Optical densities at 450 nm were deter-
mined using a microplate reader (Dynex), and concentra-
tions were extrapolated from standard curve data using a 
four parameter logistic model generated by GraphPad 
Prism 6 (GraphPad Software). Standard curves were 
31.25–2000 pg/ml for IL-12p70, and 7.8125–500 pg/ml for 
CCL18.
Carboxyfluorescein succinimidyl ester/Zombie‑NIR 
cytotoxicity assay
Detaching the Mφs from the tissue culture plates prior to 
performing the cytotoxicity assays resulted in poor viability; 
therefore, cytotoxicity was assessed by adding Vδ2+ T cells 
directly to adherent Mφs. Day 10 Mφs in 12-well tissue cul-
ture plates were washed twice in PBS and then cultured for 
20 min in PBS containing 1 μM carboxyfluorescein succin-
imidyl ester (CFSE; Life Technologies). Mφs were washed 
three times in complete medium and then cultured overnight 
with or without 1.52 × 106 autologous Vδ2+ T cells per well 
in 2 ml complete medium to obtain an E:T ratio of 2:1 based 
on the initial seeding density of monocytes. For some experi-
ments Vδ2+ T cells were pre-treated for 2 h with or with-
out 100 ng/ml concanamycin A (CMA; Abcam) or DMSO, 
then washed three times in complete medium prior to being 
cultured with Mφs. Non-adherent cells were collected and 
adherent cells detached from the tissue culture plates as 
described in “Flow cytometry”. All cells were washed in 
PBS and then labelled with Zombie-NIR live/dead cell dis-
crimination dye according to the manufacturer’s instruc-
tions (Biolegend). Zombie-NIR binds to amine groups on 
proteins, but does not penetrate an intact plasma membrane. 
Live cells have relatively low expression because only cell 
surface proteins are available for binding, whereas dead cells 
exhibit higher levels of expression because their compro-
mised plasma membrane permits binding to both extracel-
lular and intracellular proteins. After 15 min at room tem-
perature, cells were washed in complete medium and fixed in 
CellFIX. Samples were acquired on an LSR II flow cytom-
eter and analysed using FlowJo software. All comparatively 
analysed samples were acquired on the same day.
CD107 mobilisation assay
Day 10 Mφs in 96-well tissue culture plates were washed 
three times in PBS and then cultured for 5 h with 1.52 × 105 
autologous Vδ2+ T cells per well in 200 μl complete medium 
to obtain an E:T ratio of 2:1 based on the initial seeding 
density of monocytes. Allophycocyanin-conjugated mouse 
anti-human CD107a (clone H4A3; Biolegend) and FITC-
conjugated mouse anti-human CD107b (clone H4B4; Bio-
legend) or matched isotype controls were added directly to 
the wells at the start of the co-culture along with 1 μg/ml of 
monensin to neutralise intracellular acidity. Cells were then 
collected and labelled with PE-conjugated mouse anti-human 
Vδ2 (clone 123R3; Miltenyi Biotec) and PerCP-conjugated 
mouse anti-human CD3 (clone SK7; Biolegend) as described 
in “Flow cytometry”. Samples were acquired on an LSR II 
flow cytometer and analysed using FlowJo software. All com-
paratively analysed samples were acquired on the same day.
Statistical analyses
Data in Figs. 1b, c, 3b, d and 4c were analysed by repeated 
measures one-way or two-way ANOVA and compari-
sons between means carried out using either Tukey’s 
or Sidak’s multiple comparison tests (GraphPad Prism 
6). *, **, *** and **** were used to indicate p values 
of <0.05, <0.01, <0.001 and <0.0001, respectively. Gauss-
ian distributions were assumed. Data in Fig. 2b included a 
three-way (3 × 2 × 2) factorial design repeated six times 
using cells from six different donors. The three factors 
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were Mφ type (M0, M1 and M2), ±ZA and ±Vδ2 cells. 
Data in Fig. 4b were a three-way (3 × 2 × 4) factorial 
design repeated five times using cells from five differ-
ent donors. The three factors were Mφ type (M0, M1 and 
M2), ±ZA and ±Vδ2 cells (−Vδ2, +Vδ2, +Vδ2[DMSO] 
and +Vδ2[CMA]). Data in Figs. 2b and 4b were analysed 
by three-way ANOVA and comparisons between means 
carried out using Fisher’s least significant difference (LSD; 
Genstat 18). Assumptions underlying the analysis were 
checked using the diagnostic plots produced by the soft-
ware. LSDs at the 5, 1 and 0.1% level are depicted by black 
intervals, and differences in the means that were greater 
than this interval were deemed significant to an equivalent 
p value of <0.05, <0.01 and <0.001, respectively.
Results
ZA did not alter M1 or M2 markers on Mφs
We differentiated monocytes from the peripheral blood of 
healthy donors into Mφs and treated them with IFN-γ or 
IL-4 to generate M1 and M2 Mφs, respectively. We then 
characterised these Mφs based on their expression of 
markers for M1 Mφs (CD64 and IL-12p70) and M2 Mφs 
(CD206 and CCL18) [19, 22]. M1 Mφs had upregu-
lated expression of CD64, whereas M2 Mφs had down-
regulated CD64 and upregulated CD206 (Fig. 1a, b). 
Although, statistically, we observed significantly higher 
levels of CD206 on M1 Mφs compared with M0 Mφs 
in terms of percentage expression, this was not consist-
ent for all donors and not statistically significant in terms 
of relative MFI (Fig. 1b). Mφs were then cultured over-
night with or without LPS to measure the production of 
IL-12p70 and CCL18, respectively. M1 Mφs produced 
more IL-12p70 than M0 and M2 Mφs, whereas M2 Mφs 
produced more CCL18 than M0 and M1 Mφs (Fig. 1c). 
We also tested whether ZA—added for the last 18 h of 
culture—had any effect on these markers and found little 
or no difference between untreated and ZA-treated Mφs 
(Fig. 1). Taken together, these data validate our proto-
col for generating M1 and M2 Mφs and show that ZA 
does not alter the M1 and M2 profile of the Mφs in this 
system.
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Fig. 2  Vδ2+ T cell cytotoxicity towards ZA-treated M1 and 
M2 Mφs. M0, M1 and M2 Mφs treated with or without ZA for the 
last 18 h of culture were labelled with CFSE and cultured overnight 
with or without autologous Vδ2+ T cells. Flow cytometry was then 
used to measure Zombie-NIR expression. a Representative flow 
cytometry contour plots from one of six donors showing the gating 
strategy used to determine Zombie-NIR expression in M0 Mφs. Mφs 
were gated based on FSC and SSC using G1.  CFSE+ cells within G1 
were gated using G2. The percentage of Zombie-NIRhigh cells (i.e. 
dead cells) within G1 + G2 was then determined using G3. Num-
bers on the contour plots are percentages of cells within G3. b Indi-
vidual data points and means for six donors. Data were analysed by 
three-way ANOVA and comparisons between means carried out using 
Fisher’s LSD tests. The 5, 1 and 0.1% LSDs are depicted by the black 
intervals
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ZA‑rendered M1 and M2 Mφs susceptible to Vδ2+ T 
cell cytotoxicity
To obtain sufficient cell numbers for cytotoxicity assays, 
we stimulated Vδ2+ T cell expansion prior to isolation. 
Vδ2+ T cell expansion was observed in PBMCs treated 
with ZA and IL-2 for 9 days, as shown by increased fre-
quencies of Vδ2+CD3+ cells (supplementary Fig. 2). 
Vδ2+ T cells were purified by sequentially depleting 
dead cells and non-γδ T cells (mean ± standard deviation 
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Fig. 3  Expression of perforin and mobilisation of CD107a and 
CD107b in Vδ2+ T cells. a, b Flow cytometry was used to meas-
ure the expression of perforin by Vδ2+ T cells in PBMCs cultured 
with ZA and IL-2 for 0, 1 and 9 days. a Representative flow cytom-
etry plots from one of three donors showing perforin expression in 
Vδ2+ T cells. Lymphocytes were gated based on FSC and SSC using 
G1. Note that G1 was extended at day 9 to incorporate blast cells. 
Vδ2+CD3+ cells within G1 were gated using G2. Percentage expres-
sion and MFI of perforin within G1 + G2 was then assessed. Unfilled 
overlays = test, filled overlays = isotype. Numbers on the histo-
gram plots are percentage of cells within the marker. b Mean ± SD 
for three donors. Test MFIs for the total G1 + G2 population were 
divided by the isotype controls to obtain relative MFIs. Data were 
analysed by repeated measures one-way ANOVA and comparisons 
between means carried out using Tukey’s multiple comparison tests. 
c, d Vδ2+ T cells were cultured with or without autologous M0, M1 
or M2 Mφs that had been treated with or without ZA for the last 18 h 
of culture. Flow cytometry was used to measure the expression of 
CD107a and CD107b by Vδ2+ T cells. c Representative flow cytom-
etry contour plots from one of three donors showing CD107a and 
CD107b expression on gated Vδ2+CD3+ cells. Lymphocytes were 
gated based on FSC and SSC using G1. Vδ2+CD3+ cells within G1 
were gated using G2. Percentage expression of CD107a and CD107b 
within G1 + G2 was then assessed. Quadrants were set against the 
Vδ2 alone controls, and separate quadrants were generated for iso-
type and test. Numbers are percentages of cells contained within the 
upper right quadrants. d Individual data points and means for three 
donors. Data were analysed by repeated measures two-way ANOVA 
and comparisons between means carried out using Sidak’s multiple 
comparison tests. For b and d, *, **, *** and **** indicate p values 
of <0.05, <0.01, <0.001 and <0.0001, respectively
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(SD) for the percentage of Vδ2+CD3+ cells from four 
donors = 97.2 ± 1.8; supplementary Fig. 2). The per-
centage of Vδ2+CD3+ cells at day 0 and day 9 pre-deple-
tion of dead cells and non-γδ T cells was not assessed 
routinely; however, purities at day 9 post-depletion 
were assessed for all isolations performed in this study 
(mean ± SD for 14 isolations = 97.7 ± 1.8). We con-
ducted preliminary experiments to determine the optimal 
E:T ratio and ZA concentration for Vδ2+ T cell-mediated 
cytotoxicity against ZA-treated Mφs (supplementary 
Fig. 3). These experiments showed Vδ2+ T cell cytotox-
icity and degranulation against Mφs treated with 10 μM, 
but not 1 μM ZA (supplementary Fig. 3). Furthermore, 
they showed marked killing at the lowest E:T ratio of 2:1 
(supplementary Fig. 3). Using the 10 μM concentration 
of ZA and 2:1 E:T ratio, we found that ZA had little or no 
effect on Mφ viability in the absence of Vδ2+ T cells, and 
Vδ2+ T cells did not induce cell death in Mφs that had 
not been treated with ZA (Fig. 2a, b). However, there was 
a marked increase in the amount of cell death in Mφs that 
were pre-treated with ZA and then cultured with Vδ2+ 
T cells (Fig. 2a, b). Although, statistically, Vδ2+ T cell-
mediated killing of ZA-treated M1 Mφs was significantly 
higher than that of M0 Mφs, the difference was relatively 
small and no statistically significant difference was found 
between M1 and M2 Mφs (Fig. 2b). These results suggest 
that Vδ2+ T cells are cytotoxic towards ZA-treated Mφs 
irrespective of their M0, M1 and M2 phenotype.
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Fig. 4  The effect of concanamycin A on Vδ2+ T cell cytotoxicity 
towards ZA-treated Mφs. M0, M1 and M2 Mφs treated with or with-
out ZA for the last 18 h of culture were labelled with CFSE and then 
cultured overnight with or without autologous Vδ2+ T cells that had 
been pre-treated for 2 h with or without CMA (100 ng/ml) or DMSO. 
Flow cytometry was then used to measure Zombie-NIR expression. a 
Representative flow cytometry contour plots for M0 Mφs from one of 
five donors. The percentage of Zombie-NIRhigh cells (i.e. dead cells) 
within  CFSE+ Mφs was determined using the G1 + G2 + G3 gat-
ing strategy described in Fig. 2. Numbers on the plots are percent-
ages of cells within G3. b Individual data points and means for five 
donors. Data were analysed by three-way ANOVA and comparisons 
between means carried out using Fisher’s LSD tests. The 0.1% LSD 
is depicted by the black interval. c Data in b was expressed as per-
centage inhibition. Within the +ZA data sets, the percentage of dead 
Mφs in the absence of Vδ2+ T cells (i.e. background cell death) was 
subtracted from that induced by the DMSO- and CMA-treated Vδ2+ 
T cells. The corrected values for Mφ cell death induced by CMA-
treated Vδ2+ T cells were then expressed as a percentage of the cor-
rected values for Mφ cell death induced by DMSO-treated Vδ2+ T 
cells. These values were then converted to percentage inhibition by 
subtracting them from 100%. Data were analysed by repeated meas-
ures one-way ANOVA and comparisons between means carried out 
using Tukey’s multiple comparison tests. ** Indicates a p value <0.01
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Vδ2+ T cells expressed perforin and degranulated 
when cultured with ZA‑treated Mφs
Perforin has been shown previously to play a role in γδ T 
cell cytotoxicity towards tumour cell lines [23, 24]; there-
fore, we tested whether perforin contributes to Vδ2+ T cell 
cytotoxicity towards ZA-treated Mφs. We measured per-
forin expression by Vδ2+ T cells before, during and after 
expansion with ZA and IL-2. We found that, although 
resting Vδ2+ T cells expressed little or no perforin, it was 
markedly upregulated after 1 day of culture with ZA and 
IL-2 (Fig. 3a, b). After 9 days of culture with ZA and IL-2, 
perforin was downregulated but still expressed by Vδ2+ T 
cells (Fig. 3a, b). We also measured perforin expression in 
expanded and isolated Vδ2+ T cells from six donors and 
found consistent expression in terms of percentage expres-
sion (mean ± SD = 1.2 ± 0.5 vs. 23.9 ± 7.6 for isotype and 
test, respectively) and MFI (mean ± SD = 227.8 ± 15.2 
vs. 490.7 ± 104.6 for isotype and test, respectively). To 
determine if Vδ2+ T cells release perforin when cultured 
with ZA-treated Mφs, we measured the mobilisation of lys-
osomal-associated membrane protein 1 and 2 (i.e. CD107a 
and CD107b) to the surface of Vδ2+ T cells. CD107a—and 
to a lesser extent CD107b—was expressed on Vδ2+ T cells 
that were isolated from PBMCs after 9 days of culture with 
ZA and IL-2 (Fig. 3c). This may represent residual CD107 
expression from the monocyte-dependent degranulation 
that is induced when PBMCs are exposed to ZA [20]. Vδ2+ 
T cells upregulated expression of CD107a and CD107b 
on their cell surface when cultured with ZA-treated Mφs 
compared with untreated Mφs (Fig. 3c, d). These data sug-
gest that Vδ2+ T cells express perforin and degranulate in 
response to ZA-treated Mφs, thus implicating a role for 
perforin in Vδ2+ T cell cytotoxicity towards ZA-treated 
Mφs.
Vδ2+ T cell cytotoxicity towards ZA‑treated Mφs was 
sensitive to concanamycin A
To explore further the potential role of perforin in Vδ2+ 
T cell cytotoxicity towards ZA-treated Mφs, we repeated 
the cytotoxicity assays shown in Fig. 2, but this time pre-
treated Vδ2+ T cells with the  H+-ATPase inhibitor CMA. 
CMA blocks acidification of cytolytic granules, which 
inhibits perforin-mediated but not Fas ligand-mediated 
cytotoxicity [25]. We found that pre-treating Vδ2+ T cells 
with CMA reduced their cytotoxicity towards Mφs com-
pared with DMSO controls (Fig. 4a, b). We calculated the 
percentage inhibition for Vδ2+ T cell cytotoxicity towards 
M0, M1 and M2 Mφs and found that Vδ2+ T cell cytotox-
icity towards M0 Mφs was more sensitive to CMA than 
towards M1 Mφs (Fig. 4c). To determine whether CMA 
had an effect on Vδ2+ T cell viability, we applied a gate 
to  CFSE− cells and calculated the percentage of Zombie-
NIRlow cells (supplementary Fig. 4a). There was a discern-
ible reduction in Vδ2+ T cell viability in the presence of 
ZA-treated Mφs compared with untreated Mφs; however, 
there was little or no difference in Vδ2+ T cell viability 
between the CMA and DMSO treatment groups (supple-
mentary Fig. 4b). These findings suggest that Vδ2+ T cell 
cytotoxicity towards ZA-treated Mφs is sensitive—at least 
in part—to CMA, thus implicating a role for perforin.
Discussion
Vδ2+ T cells in the peripheral blood of humans are regarded 
as sentinels against infection [26] and malignant transfor-
mation [27]. They express the inflammatory homing recep-
tors chemokine (C–C motif) receptor 5 and chemokine 
(C–X–C motif) receptor 3 [28] and thus infiltrate sites of 
infection [29] as well as the inflammatory microenviron-
ment of diseased tissues such as tumours [30, 31]. Mφs are 
abundant in these tissues and are likely to interact closely 
with infiltrating Vδ2+ T cells. We explored the potential 
interaction between Vδ2+ T cells and Mφs in vitro and 
found that ZA can render M1 and M2 Mφs susceptible to 
Vδ2+ T cell cytotoxicity in a perforin-dependent manner.
Zoledronic acid has a high affinity for hydroxyapatite 
[32] and thus binds rapidly to bone following i.v. infusion 
[33]. Therefore, the Mφs most likely to be exposed to ZA 
are those associated with bone and/or the surrounding tis-
sues: for example, the TAMs in bone-related cancers such 
as osteosarcoma, myeloma and secondary bone metastases 
associated with cancers of the prostate, lung and breast. 
Following i.v. infusion, NBPs may also reach tissues other 
than bone. Intravital imaging in a murine model of breast 
cancer showed that a fluorescently labelled NBP—given 
by i.v. injection—leaked from the vasculature of mam-
mary tumours and bound rapidly to granular microcalcifi-
cations, which were subsequently engulfed by TAMs [15]. 
The NBP was not retained in cells other than Mφs, nor was 
it retained in B16 tumours, which lack microcalcifications 
[15]. This study suggests that calcified tissues other than 
bone can also accumulate NBPs [15]. The lack of cytotox-
icity and degranulation at 1 μM ZA that was observed in 
our preliminary optimisation experiments suggests that the 
Mφs most likely to be targeted by Vδ2+ T cells following 
ZA treatment are those associated with calcified tissues 
where the drug is likely to accumulate, which has impor-
tant implications regarding the in vivo effects of this drug. 
It is worth noting that uptake of ZA by Mφs in vivo may be 
markedly different using other methods of delivery such as 
liposome or nanoparticle encapsulation [34, 35] and local-
ised injection. At the cellular level, experiments conducted 
in vitro suggest that ZA is taken up by myeloid cells such 
1213Cancer Immunol Immunother (2017) 66:1205–1215 
1 3
as monocytes, Mφs and osteoclasts via the process of fluid 
phase endocytosis [36, 37].
Zoledronic acid inhibits farnesyl pyrophosphate syn-
thase of the mevalonate pathway, which has been shown 
in vitro to induce apoptosis directly in the murine Mφ-like 
cell line J774.2 [38]. A potential mechanism for this 
effect is accumulation of the pro-apoptotic analogue of 
ATP, Apppl, which has been reported to accumulate in 
ZA-treated cells such as osteoclasts and MCF-7 cells [4]. 
Interestingly, ZA did not affect the viability of Mφs in our 
experiments; however, we used relatively short exposure 
times and did not look at markers of early stage apoptosis 
such as surface expression of phosphatidyl serine. Inhibi-
tion of farnesyl pyrophosphate synthase may also modulate 
the differentiation and function of Mφs. For example, when 
monocyte-derived M2 Mφs were differentiated in the pres-
ence of ZA, they had reduced expression of CD206 and 
IL-10, and an impaired capacity to promote angiogenesis 
and tumour cell invasion [39]. ZA also inhibited tumour 
growth in a murine model of cervical cancer, which cor-
related with reduced angiogenesis and decreased produc-
tion of matrix metallopeptidase 9 by Mφs proximal to and 
associated with tumours [40]. Furthermore, ZA reduced the 
onset and growth of tumours in a murine model of breast 
cancer, which correlated with reduced vascularisation of 
the tumour, reduced numbers of TAMs, and repolarisa-
tion of TAMs from an M2 to M1 phenotype [41]. Taken 
together, these studies suggest that ZA can modulate the 
differentiation of Mφs towards an M1 phenotype. To the 
best of our knowledge, Vδ2+ T cell targeting of ZA-treated 
M1 and M2 Mφs—as suggested by our data—has been 
previously unreported and broadens our understanding of 
the effects of ZA on Mφs. Importantly, mice do not develop 
the Vδ2+ T cell subset that responds to ZA-induced accu-
mulation of IPP because they lack the gene for butyrophilin 
3A1 [42], thus highlighting the importance of using human 
cells for this study.
Our data suggests that ZA has the potential to kill M1 
and M2 Mφs indirectly within tissues that are exposed to 
the drug and infiltrated by Vδ2+ T cells. Tumours con-
tain an abundant population of Mφs, which typically 
express M2 markers and correlate with a poor prognosis 
[43]. In breast cancer, CCL18 production by TAMs pro-
motes angiogenesis and thus supports tumour growth and 
dissemination [44]. Furthermore, M2 Mφs in the bone 
marrow of multiple myeloma patients have been shown 
to protect malignant cells from chemotherapy-induced 
apoptosis [45, 46]. In contrast, osteosarcomas can contain 
relatively high percentages of M1 Mφs, which are associ-
ated with reduced metastases and improved survival [47]. 
The potential for ZA to render Mφs susceptible to Vδ2+ 
T cells may be beneficial or detrimental depending on 
which type of Mφ is present in the tumour. For example, 
it may be beneficial in patients with breast cancer or mye-
loma and could explain the promising responses to ZA 
reported for clinical trials in these cancer types [48, 49], 
whereas it may be counterproductive in osteosarcoma.
It is important to note that our study has focussed on 
the killing capacity of activated Vδ2+ T cells. Although 
it would be interesting to compare the cytotoxicity of 
resting and activated Vδ2+ T cells, the relatively low fre-
quency of Vδ2+ T cells in peripheral blood meant that 
we were unable to isolate the number of resting Vδ2+ T 
cells required to perform the cytotoxicity assays used in 
this study. Whether or not i.v. infusion of ZA—combined 
with i.v. or s.c. IL-2—can activate peripheral blood Vδ2+ 
T cells in vivo is a point of contention. Current hypoth-
eses state that peripheral blood monocytes take up ZA 
following i.v. infusion and subsequently activate Vδ2+ T 
cells [37]; indeed, proliferation and/or differentiation of 
peripheral blood Vδ2+ T cells has been reported in some 
patients receiving ZA and IL-2 [9–11]. However, Vδ2+ T 
cell responses were not observed in all patients [50] and 
it is unclear whether this is due to lack of activation or 
detection. Importantly, Vδ2+ T cells that are pre-activated 
may be more cytotoxic than resting, and thus ZA-induced 
targeting of Mφs by Vδ2+ T cells in vivo may be subop-
timal in patients for whom ZA and IL-2 treatment fails 
to activate their circulating Vδ2+ T cells, thus highlight-
ing the importance of effective Vδ2+ T cell priming in the 
periphery.
In our study, Vδ2+ T cell cytotoxicity towards M0, M1 
and M2 Mφs was sensitive—at least in part—to the per-
forin inhibitor CMA, thus implicating a role for perforin 
[25]. Interestingly, CMA did not inhibit cytotoxicity com-
pletely, and the degree of inhibition varied between the dif-
ferent types of Mφ; specifically, Vδ2+ T cell cytotoxicity 
towards M0 Mφs was more sensitive to CMA than towards 
M1 Mφs. If, in our assays, CMA blocked perforin com-
pletely, our data would suggest that other mechanisms of 
cell-mediated cytotoxicity are involved and that the contri-
bution of perforin versus other mechanisms of cytotoxic-
ity varies between the different types of Mφ. Indeed, Vδ2+ 
T cells have been shown to kill target cells through the 
expression of Fas ligand and TRAIL [51]. However, if per-
forin blockade was incomplete, the variation in sensitivity 
to CMA that was observed between the different types of 
Mφ could also be attributed to differences in their suscepti-
bility to perforin-mediated killing under conditions of sub-
optimal perforin activity. Nonetheless, our data suggest that 
perforin plays a role, which provides a useful mechanistic 
marker for exploring this concept in vivo.
In conclusion, this study sheds light on a potential inter-
action between Vδ2+ T cells and Mφs following ZA treat-
ment and suggests a mechanism of action for this drug that 
may help its future development in cancer immunotherapy.
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